{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:48:00Z","timestamp":1791870480129,"version":"4.3.4"},"reference-count":33,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"unspecified","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Research and Development, County Council of Vasternorrland","award":["LVNFOU929591"],"award-info":[{"award-number":["LVNFOU929591"]}]},{"name":"Department of Research and Development, County Council of Vasternorrland","award":["LVNFOU979649"],"award-info":[{"award-number":["LVNFOU979649"]}]},{"name":"The Swedish Heart and Lung foundation","award":["20200766"],"award-info":[{"award-number":["20200766"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,6,26]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>The use of direct oral anticoagulants (DOACs) as stroke prophylaxis in patients with non-valvular atrial fibrillation (NVAF) has increased steadily since the introduction in 2011. In Sweden today, more patients are treated with DOACs than with warfarin. However, it is not shown that an increased proportion of DOAC prescriptions correlates to lower event rates of stroke and systemic embolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aims to investigate whether the increased prescription of DOACs in Sweden correlates with lower event rates for all-cause stroke, systemic embolism and bleeding complications, using real-life data for the whole NVAF population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Nationwide retrospective register study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Data were obtained from the Swedish National Patient Registry, covering patients aged 18 years or older with NVAF, between 1 January 2014, and 31 December 2017. Exposure to oral anticoagulants was determined based on pharmaceutical data, calculating treatment duration by the number of pills dispensed and the prescribed daily usage rate. Baseline characteristics and endpoints were collected from hospital administrative registers using International Classification of Diseases, 10th edition (ICD-10) codes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>All patients with NVAF were identified using ICD-10 codes during the study period. Entry criteria included having a first recorded atrial fibrillation diagnosis after 1 January 2014 or being previously diagnosed with atrial fibrillation before 2014 but still receiving care after this date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>The outcomes were event rates (per 100 person-years) of ischaemic stroke, systemic embolism, all-cause stroke, major bleeding and intracranial bleeding (including haemorrhagic stroke). Event rates were calculated and compared across the study period using Cox proportional hazard models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the total NVAF population, the proportional decrease in event rates (per 100 treatment years) in 2017 compared with 2014 was ischaemic stroke 24% (1.70\u20131.30), all-cause mortality 4% (9.40\u20139.00), all-cause stroke 24% (2.10\u20131.60) and all-cause stroke and systemic embolism 23% (2.20\u20131.70). During the same time, the proportion of major bleeding and intracranial bleeding rates, including haemorrhagic stroke, also decreased: 5% (2.00\u20131.90), 6% (0.68\u20130.64) and 17% (0.30\u20130.25), respectively. DOACs use increased from 4.1% to 28.3% in the total population and from 22.7% to 60.9% in newly diagnosed patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the initial years following the introduction when DOAC uptake in the population was high, an increasing proportion of Swedish NVAF patients receiving DOACs was accompanied by lower event rates of all-cause stroke and systemic embolism, ischaemic stroke and all-cause mortality, intracranial bleeding and major bleeding, highlighting the improved risk-benefit balance of DOACs in stroke prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-100960","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T08:56:04Z","timestamp":1752569764000},"page":"e100960","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Increased direct oral anticoagulant use and event rates in non-valvular atrial fibrillation: a nationwide retrospective registry study in Sweden"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-4975","authenticated-orcid":false,"given":"Hayder","family":"Kadhim","sequence":"first","affiliation":[{"name":"Department of Public Health and Clinical Medicine, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2131-4255","authenticated-orcid":false,"given":"Martin","family":"Jansson","sequence":"additional","affiliation":[{"name":"Department of Public Health and Clinical Medicine, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1239-6239","authenticated-orcid":false,"given":"Sara","family":"Sj\u00e4lander","sequence":"additional","affiliation":[{"name":"Department of Public Health and Clinical Medicine, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilhelm","family":"Sj\u00f6gren","sequence":"additional","affiliation":[{"name":"Department of Public Health and Clinical Medicine, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1990-6836","authenticated-orcid":false,"given":"Fredrik","family":"Bj\u00f6rck","sequence":"additional","affiliation":[{"name":"Department of Public Health and Clinical Medicine, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2141-6086","authenticated-orcid":false,"given":"Henrik","family":"Renlund","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3298-1555","authenticated-orcid":false,"given":"Marie","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Statistics, USBE, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Norrving","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Neurology, Sk\u00e5ne University Hospital, Lund University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-1186","authenticated-orcid":false,"given":"Anders","family":"Sj\u00e4lander","sequence":"additional","affiliation":[{"name":"Department of Public Health and Clinical Medicine, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"2025121513503526000_15.7.e100960.1","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.hoc.2016.05.002","article-title":"Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation","volume":"30","author":"Plitt","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"2025121513503526000_15.7.e100960.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007432"},{"key":"2025121513503526000_15.7.e100960.3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.7326\/0003-4819-147-8-200710160-00018","article-title":"Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation","volume":"147","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"2025121513503526000_15.7.e100960.4","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"2025121513503526000_15.7.e100960.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.055079"},{"key":"2025121513503526000_15.7.e100960.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.01.033"},{"key":"2025121513503526000_15.7.e100960.7","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.7.677"},{"key":"2025121513503526000_15.7.e100960.8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(14)61106-5","article-title":"New oral anticoagulants in patients with atrial fibrillation \u2013 Authors\u2019reply","volume":"384","author":"Ruff","year":"2014","journal-title":"The Lancet"},{"key":"2025121513503526000_15.7.e100960.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03677.x"},{"key":"2025121513503526000_15.7.e100960.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608223350802"},{"key":"2025121513503526000_15.7.e100960.11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.12-1119","article-title":"Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence","volume":"143","author":"Rose","year":"2013","journal-title":"Chest"},{"key":"2025121513503526000_15.7.e100960.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"2025121513503526000_15.7.e100960.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"2025121513503526000_15.7.e100960.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"2025121513503526000_15.7.e100960.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"2025121513503526000_15.7.e100960.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"key":"2025121513503526000_15.7.e100960.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"2025121513503526000_15.7.e100960.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-009-9404-1"},{"key":"2025121513503526000_15.7.e100960.19","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12613"},{"key":"2025121513503526000_15.7.e100960.20","unstructured":"REGISTER, T. S. S . Riksstrokes \u00e5rsrapport 2019 (in Swedish) [annual report of riksstroke 2019]. 2020. Available: http:\/\/www.riksstroke.org\/sve\/forskning-statistik-och-verksamhetsutveckling\/forskning\/arsrapporter\/ [Accessed 11 Dec 2020]."},{"key":"2025121513503526000_15.7.e100960.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018702","article-title":"Development and validation of the Swedish national stroke register Riksstroke\u2019s questionnaires in patients at 3 and 12 months after stroke: a qualitative study","volume":"8","author":"Palmcrantz","year":"2018","journal-title":"BMJ Open"},{"key":"2025121513503526000_15.7.e100960.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-017-0316-1"},{"key":"2025121513503526000_15.7.e100960.23","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13070","article-title":"Epidemiology of atrial fibrillation","volume":"72","author":"Zulkifly","year":"2018","journal-title":"Int J Clin Pract"},{"key":"2025121513503526000_15.7.e100960.24","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-317006"},{"key":"2025121513503526000_15.7.e100960.25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2017.08.004","article-title":"Ischemic stroke rates decline in patients with atrial fibrillation as anticoagulants uptake improves: A Swedish cohort study","volume":"158","author":"Mochalina","year":"2017","journal-title":"Thromb Res"},{"key":"2025121513503526000_15.7.e100960.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026645","article-title":"Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016","volume":"9","author":"Maura","year":"2019","journal-title":"BMJ Open"},{"key":"2025121513503526000_15.7.e100960.27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.6424","article-title":"Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage","volume":"3","author":"Tsai","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025121513503526000_15.7.e100960.28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-731638"},{"key":"2025121513503526000_15.7.e100960.29","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1161\/STROKEAHA.118.022636","article-title":"Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants","volume":"49","author":"Shpak","year":"2018","journal-title":"Stroke"},{"key":"2025121513503526000_15.7.e100960.30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11239-014-1136-8","article-title":"Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use","volume":"40","author":"Wilke","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"2025121513503526000_15.7.e100960.31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12872-020-01330-6","article-title":"Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study","volume":"20","author":"Liu","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"2025121513503526000_15.7.e100960.32","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.017683"},{"key":"2025121513503526000_15.7.e100960.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.10.063"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-100960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T21:50:43Z","timestamp":1765835443000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-100960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,15]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2025-100960"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-100960","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}